Efficacy of antiplatelets in deep venous thrombosis

Venous thromboembolism (VTE) is the third most common cardiovascular disease in the world. Every year, 30,000 people in Australia develop VTE, at a cost of $1.72 billion to the Australian health system.

Pharmacists in 2023: roles and remuneration

Better remuneration and career support are key to the future of pharmacists’ roles. The pharmacy profession provides a much broader range of health services...

Quick Q&A with Katherine Higgins MPS

Jennifer Cooke, the Editor of Australian Pharmacist, talks with Katherine Higgins, a pharmacist in South Perth, Western Australia.

Lead-up to medicine error

Mr Sotirios Temopoulos had a medical history that included multiple myeloma with a myelomataus lesion in his cervical spine, in which he was prescribed...

Pharmacy Board’s measured step on prescribing

The Pharmacy Board of Australia has recognised that pharmacists should be able to prescribe under two monitored models of prescribing, in a move welcomed...

Nasal swab offers hope for reducing vancomycin use

A study has found a pharmacy-driven protocol using nasal swabs to assess methicillin‑resistant Staphylococcus aureus (MRSA) in pneumonia cases holds promise for reducing unnecessary...